Cellular Reprogramming, Genome Editing, and Alternative CRISPR Cas9 Technologies for Precise Gene Therapy of Duchenne Muscular Dystrophy
In the past decade, the development of two innovative technologies, namely, induced pluripotent stem cells (iPSCs) and the CRISPR Cas9 system, has enabled researchers to model diseases derived from patient cells and precisely edit DNA sequences of interest, respectively. In particular, Duchenne musc...
Saved in:
Main Authors: | Peter Gee, Huaigeng Xu, Akitsu Hotta |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-01-01
|
Series: | Stem Cells International |
Online Access: | http://dx.doi.org/10.1155/2017/8765154 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Optimizing Bone Health in Duchenne Muscular Dystrophy
by: Jason L. Buckner, et al.
Published: (2015-01-01) -
Duchenne muscular dystrophy: recent insights in brain related comorbidities
by: Cyrille Vaillend, et al.
Published: (2025-02-01) -
Prenatal Diagnosis of the Duchenne Muscular Dystrophy. A Family Presentation
by: Humberto Perera Navarro, et al.
Published: (2007-05-01) -
Sugammadex and Reversal of Neuromuscular Block in Adult Patient with Duchenne Muscular Dystrophy
by: Ahmed Abdelgawwad Wefki Abdelgawwad Shousha, et al.
Published: (2014-01-01) -
Unraveling the Genetic Heartbeat: Decoding Cardiac Involvement in Duchenne Muscular Dystrophy
by: Valeria Novelli, et al.
Published: (2025-01-01)